Nalaganje...
Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab(†)
BACKGROUND. The use of bevacizumab for recurrent glioblastoma is controversial. Here we show data on patients who responded to bevacizumab, then stopped bevacizumab for any reason other than progression and were rechallenged with bevacizumab at the time of subsequent progression. METHODS. This retro...
Shranjeno v:
| izdano v: | Neurooncol Pract |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6655406/ https://ncbi.nlm.nih.gov/pubmed/31385992 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nop/npw004 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|